{"schema_version":"secwatch.filing_event.v1","accession":"0000950103-24-000236","form_type":"8-K","ticker":"ADCT","cik":"0001771910","company_name":"ADC Therapeutics SA","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.473521+00:00","generated_at":"2026-06-07T04:08:31.224535+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ADC Therapeutics reports preliminary ZYNLONTA Q4 net sales ~$16.5M; cash ~$278.5M","bullets":["Preliminary ZYNLONTA Q4 2023 net sales ~$16.5M, double-digit percentage increase from Q3 2023.","Cash and cash equivalents ~$278.5M at Q4-end; cash runway extended to Q4 2025 (prev. mid-2025).","LOTIS-7 combo trial cleared first dosing cohort with no DLT; first 5 evaluable patients all showed response.","ADCT-601 (AXL) reached MTD; early antitumor activity in monotherapy and combination; dose optimization ongoing.","Discontinued ADCT-901 (KAAG1) due to limited efficacy; reallocating capital to prioritized pipeline programs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950103-24-000236","json":"https://secwatch.observer/filing/0000950103-24-000236.json","markdown":"https://secwatch.observer/filing/0000950103-24-000236.md","text":"https://secwatch.observer/filing/0000950103-24-000236.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324000236/0000950103-24-000236-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1771910/000095010324000236/dp204839_8k-2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:08:31.224535+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}